Randomized, double-blind, phase II study of temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer
M. Catherine Pietanza, Saiama N. Waqar, Lee M. Krug, Afshin Dowlati, Christine L. Hann, Alberto Chiappori, Taofeek K. Owonikoko, Kaitlin M. Woo, Robert J. Cardnell, Junya Fujimoto, Lihong Long, Lixia Diao, Jing Wang, Yevgeniva Bensman, Brenda Hurtado, Patricia de Groot, Erik P. Sulman, Ignacio I. Wistuba, Alice Chen, Martin FleisherJohn V. Heymach, Mark G. Kris, Charles M. Rudin, Lauren Averett Byers
Dive into the research topics of 'Randomized, double-blind, phase II study of temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer'. Together they form a unique fingerprint.